Daniel B. Costa
Impact in
- Pulmonary and Respiratory Medicine top 0.05%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
- Oncology top 0.2%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
Papers in
-
- Lung Cancer Treatments and Mutations 122
- Lung Cancer Diagnosis and Treatment 24
- Oncology 73
- Lung Cancer Research Studies 37
- Colorectal Cancer Treatments and Studies 25
- Cancer Immunotherapy and Biomarkers 11
- HER2/EGFR in Cancer Research 8
- Co-authors
- Susumu Kobayashi (51 shared papers)Mark S. Huberman (36 shared papers)Deepa Rangachari (49 shared papers)Hiroyuki Yasuda (11 shared papers)Paul A. VanderLaan (48 shared papers)Alice T. Shaw (12 shared papers)Beow Y. Yeap (8 shared papers)Benjamin Solomon (8 shared papers)
- Journals
- Journal of Clinical Oncology (33 papers)Journal of Thoracic Oncology (29 papers)Lung Cancer (20 papers)Clinical Lung Cancer (7 papers)Annals of Oncology (6 papers)
- Partner nations
- United StatesJapanHong Kong
In The Last Decade
Daniel B. Costa
167 papers receiving 10.4k citations
Daniel B. Costa's Hit Papers
Peers
Comparison fields: 5 of 115
- Pulmonary and Respiratory Medicine 7.7k
- Oncology 4.9k
- Cancer Research 1.6k
- Molecular Biology 3.0k
- Pathology and Forensic Medicine 528
Countries citing papers authored by Daniel B. Costa
This map shows the geographic impact of Daniel B. Costa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel B. Costa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel B. Costa more than expected).
Fields of papers citing papers by Daniel B. Costa
This network shows the impact of papers produced by Daniel B. Costa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel B. Costa. The network helps show where Daniel B. Costa may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel B. Costa, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 170 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK Hit paper breakdown → | 2009 | 1469 |
| 2 | Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib Hit paper breakdown → | 2018 | 521 |
| 3 | CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib Hit paper breakdown → | 2011 | 474 |
| 4 | Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases Hit paper breakdown → | 2015 | 468 |
| 5 | EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications Hit paper breakdown → | 2011 | 453 |
| 6 | BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations Hit paper breakdown → | 2007 | 409 |
| 7 | 2009 | 372 | |
| 8 | Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers Hit paper breakdown → | 2015 | 362 |
| 9 | Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer Hit paper breakdown → | 2011 | 324 |
| 10 | 2016 | 193 | |
| 11 | 2010 | 177 | |
| 12 | 2015 | 176 | |
| 13 | 2012 | 172 | |
| 14 | 2018 | 146 | |
| 15 | 2012 | 144 | |
| 16 | 2008 | 139 | |
| 17 | 2017 | 139 | |
| 18 | 2007 | 137 | |
| 19 | 2006 | 132 | |
| 20 | 2015 | 131 |
About Daniel B. Costa
Daniel B. Costa is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research and Hematology, having authored 170 papers that have together received 10.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (122 papers), Lung Cancer Research Studies (37 papers), Colorectal Cancer Treatments and Studies (25 papers), Lung Cancer Diagnosis and Treatment (24 papers), Cancer Genomics and Diagnostics (18 papers), Cancer therapeutics and mechanisms (13 papers), Cancer Immunotherapy and Biomarkers (11 papers) and HER2/EGFR in Cancer Research (8 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (7.7k citations), Oncology (4.9k citations), Cancer Research (1.6k citations), Molecular Biology (3.0k citations) and Pathology and Forensic Medicine (528 citations). Daniel B. Costa has collaborated with scholars based in United States, Japan and Hong Kong. Frequent co-authors include Susumu Kobayashi, Mark S. Huberman, Deepa Rangachari, Hiroyuki Yasuda, Paul A. VanderLaan, Alice T. Shaw, Beow Y. Yeap, Benjamin Solomon, Kim-Son H. Nguyen and Keith D. Wilner. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Lung Cancer, Clinical Lung Cancer and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.